Ebola Virus: Pathogenesis and Countermeasure Development
- PMID: 31567063
- DOI: 10.1146/annurev-virology-092818-015708
Ebola Virus: Pathogenesis and Countermeasure Development
Abstract
Since its discovery in 1976, Ebola virus (EBOV) has caused numerous outbreaks of fatal hemorrhagic disease in Africa. The biggest outbreak on record is the 2013-2016 epidemic in west Africa with almost 30,000 cases and over 11,000 fatalities, devastatingly affecting Guinea, Liberia, and Sierra Leone. The epidemic highlighted the need for licensed drugs or vaccines to quickly combat the disease. While at the beginning of the epidemic no licensed countermeasures were available, several experimental drugs with preclinical efficacy were accelerated into human clinical trials and used to treat patients with Ebola virus disease (EVD) toward the end of the epidemic. In the same manner, vaccines with preclinical efficacy were administered primarily to known contacts of EVD patients on clinical trial protocols using a ring-vaccination strategy. In this review, we describe the pathogenesis of EBOV and summarize the current status of EBOV vaccine development and treatment of EVD.
Keywords: Ebola virus; Ebola virus disease; animal model; clinical trials; filovirus; vaccines.
Similar articles
-
Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.J Virol. 2018 May 14;92(11):e00363-18. doi: 10.1128/JVI.00363-18. Print 2018 Jun 1. J Virol. 2018. PMID: 29514907 Free PMC article.
-
Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses.Front Immunol. 2021 Aug 18;12:703986. doi: 10.3389/fimmu.2021.703986. eCollection 2021. Front Immunol. 2021. PMID: 34484200 Free PMC article.
-
[Recent Advances in Vaccines and Drugs Against the Ebola Virus].Bing Du Xue Bao. 2015 May;31(3):287-92. Bing Du Xue Bao. 2015. PMID: 26470536 Review. Chinese.
-
Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus.Front Immunol. 2018 Aug 10;9:1803. doi: 10.3389/fimmu.2018.01803. eCollection 2018. Front Immunol. 2018. PMID: 30147687 Free PMC article. Review.
-
Progress towards a vaccine against Ebola to meet emergency medical countermeasure needs.Vaccine. 2019 Nov 15;37(48):7178-7182. doi: 10.1016/j.vaccine.2017.10.111. Epub 2017 Dec 2. Vaccine. 2019. PMID: 29199040
Cited by
-
Shifting the paradigm in RNA virus detection: integrating nucleic acid testing and immunoassays through single-molecule digital ELISA.Front Immunol. 2024 Jan 3;14:1331981. doi: 10.3389/fimmu.2023.1331981. eCollection 2023. Front Immunol. 2024. PMID: 38235132 Free PMC article. Review.
-
Non-Ebola Filoviruses: Potential Threats to Global Health Security.Viruses. 2024 Jul 23;16(8):1179. doi: 10.3390/v16081179. Viruses. 2024. PMID: 39205153 Free PMC article. Review.
-
Unique Mode of Antiviral Action of a Marine Alkaloid against Ebola Virus and SARS-CoV-2.Viruses. 2022 Apr 15;14(4):816. doi: 10.3390/v14040816. Viruses. 2022. PMID: 35458549 Free PMC article.
-
Discovery of Adamantane Carboxamides as Ebola Virus Cell Entry and Glycoprotein Inhibitors.ACS Med Chem Lett. 2020 May 1;11(6):1160-1167. doi: 10.1021/acsmedchemlett.0c00025. eCollection 2020 Jun 11. ACS Med Chem Lett. 2020. PMID: 32550996 Free PMC article.
-
National burden of Ebola virus disease in Democratic Republic of the Congo: the urgency to act.Ann Med Surg (Lond). 2024 Jun 21;86(8):4579-4585. doi: 10.1097/MS9.0000000000002213. eCollection 2024 Aug. Ann Med Surg (Lond). 2024. PMID: 39118744 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
